• Biosimilars
  • Drug Development/R&D
  • All Topics
OHE OHE
Newsletter SignupSubscribe

News & Insights
  • News
  • Events
  • Insights
  • Bulletin
  • News
  • Events
  • Insights
  • Bulletin

News & Insights

  • News
  • Events
  • Insights
  • Bulletin
Newsletter SignupSubscribe
  • News
  • Events
  • Insights
  • Bulletin

Close
OHE OHE
  • Research & Publications
  • News & Insights
  • Education
  • Innovation Policy Prize
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:
  • Antimicrobial Resistance (AMR)
  • Biosimilars
  • Cell and Gene Therapies
  • Chronic Diseases
  • Combination Therapies
  • COVID-19 Research
  • Digital Health
  • Drug Development/R&D
  • Emerging Markets
  • EQ-5D and PROMs
  • Health Care Systems
  • Health Data and Statistics
  • Health Technology Assessment
  • Precision Medicine
  • Real World Evidence
  • Use of Medicines
  • Value-Based Pricing
  • Vaccine Research
  • Economics of Innovation
  • Measuring and Valuing Outcomes
  • Policy, Organisation and Incentives in Health Systems
  • Value, Affordability and Decision Making

News & Insights

  • News
  • Events
  • Insights
  • Bulletin

Education

  • Education Hub
  • OHE Graduate School
  • EVIA Programme

Innovation Policy Prize

  • The Prize Fund
  • 2022 Prize Fund

Latest Research & Publications

  • Antimicrobial Resistance (AMR)
  • Economics of Innovation

Incentivising New Antibiotics: Designing a Value-Based Delinked Pull Incentive Mechansim

ABPI_Incentivising_Antibioics_peter-pryharski-unsplash_landscape
Read more

Proposal for a General Outcome-based Value Attribution Framework for Combination Therapies

CombTher_Adobe_photoguns_portrait
Read more
© photoguns
  • Digital Health

Navigating the Landscape of Digital Health – United Kingdom

Healthcare_Adobe_elenabsl
Read more

2021 OHE Annual Report to the Charity Commission

charityreport_lina-trochez-unsplash_landscape
Read more
© Lina Trochez/Unsplash

Supporting the Era of Green Pharmaceuticals in the UK

Sustainability_AdobeStock_270582392_landscape
Read more

Quality of life and wellbeing in individuals with experience of fertility problems and assisted reproductive techniques

Quality of life assisted reproduction Cover
Read more
  • Cell and Gene Therapies
  • Value, Affordability, and…

Health Technology Assessment of Gene Therapies: Are Our Methods Fit for Purpose?

gene_therapies_national-cancer-institute-unsplash_landscape
Read more
© NCI/Unsplash
  • Drug Development/R&D
  • Economics of Innovation
  • Health Policy and Regulation

Limitations of CBO’s Simulation Model of New Drug Development as a Tool for Policymakers

CBO-US_mayer-tawfik-K4Ckc0AxgDI-unsplash_landscape
Read more
© Mayer Tawfik/Unsplash
Close
OHE
  • All Publications

    Filter by:
    • Antimicrobial Resistance (AMR)
    • Biosimilars
    • Cell and Gene Therapies
    • Chronic Diseases
    • Combination Therapies
    • COVID-19 Research
    • Digital Health
    • Drug Development/R&D
    • Emerging Markets
    • EQ-5D and PROMs
    • Health Care Systems
    • Health Data and Statistics
    • Health Technology Assessment
    • Precision Medicine
    • Real World Evidence
    • Use of Medicines
    • Value-Based Pricing
    • Vaccine Research
    • Economics of Innovation
    • Measuring and Valuing Outcomes
    • Policy, Organisation and Incentives in Health Systems
    • Value, Affordability and Decision Making
    • News
    • Events
    • Insights
    • Bulletin
    • Education Hub
    • OHE Graduate School
    • EVIA Programme
    • The Prize Fund
    • 2022 Prize Fund
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe
Back
  • News
11 min read 10th December 2020

Should We ‘Drop Dead’ from Health State Valuation?

In a new OHE Research Paper, Chris Sampson, David Parkin, and Nancy Devlin consider whether ‘dead’ must be used as an anchor in health state valuation. The authors are looking for feedback from readers to inform future research. Resource allocation…

Share:
  •  Twitter
  •  LinkedIn
  •  Facebook
  • has-icon Email

In a new OHE Research Paper, Chris Sampson, David Parkin, and Nancy Devlin consider whether ‘dead’ must be used as an anchor in health state valuation. The authors are looking for feedback from readers to inform future research.

Resource allocation decisions in health care may involve trade-offs between improving people’s quality of life and improving their longevity. The quality-adjusted life year (QALY) is used to recognise this trade-off. But is it necessary to use ‘dead’ as an anchor in health state valuation? In a new OHE Research Paper, Chris Sampson, David Parkin, and Nancy Devlin argue the case for ‘Dropping Dead’ as the anchor for health state values. And the authors would like your feedback.

By convention, the values developed to accompany generic measures of health-related quality of life, such as the EQ-5D, are anchored on a scale where 1 = full health and 0 = dead. As a result, stated preference methods used to value health states – such as time trade-off and discrete choice experiments – involve consideration of the state ‘dead’. Some health states are judged by respondents to be worse than the ‘dead’ state, meaning that they need to be assigned negative values.

In recent years, numerous researchers have identified challenges arising from anchoring at ‘dead’. Despite considerable efforts devoted to developing new methods, the need to identify negative values continues to cause fundamental problems. For instance, there is no agreement on what the lowest negative value should be.

In our new paper, we challenge the assumption that anchoring health state values at ‘dead = 0’ is a necessary condition for values to be used to estimate QALYs in cost-effectiveness analysis.

We consider five propositions:

  1. anchoring at ‘dead’ is not required by theories of scale measurement and utility;
  2. calculating QALY gains does not require a distinction between states better than and worse than dead;
  3. cost-effectiveness analysis does not require that ‘dead’ has a value relative to health states;
  4. using ‘dead’ as an anchor causes problems that make studies difficult to conduct and their results difficult to interpret; and
  5. there are alternative states to ‘dead’ that exhibit favourable properties for anchoring.

Informed by a narrative review of the literature, we find support for each proposition.

Anchoring health state values at ‘dead’ was an arbitrary choice made early in the development of health state valuation methods. Its use as an anchor has gone unchallenged for a quarter of a century and has become part of the accepted wisdom in health economics. We provide arguments to show that the use of ‘dead’ as an anchor is not only unnecessary but also undesirable because of the methodological and conceptual problems it causes. We conclude that, in valuing health states, researchers should ‘drop dead’.

But what do you think?

To ‘drop dead’ would be a relatively straightforward methodological change, with the ‘dead’ anchor simply being replaced with an alternative state (such as ‘worst health state imaginable’). However, we recognise that such a change raises fundamental questions. Therefore, we would like to hear your views. For example, we would like you to consider:

  • Do you agree that it is time to ‘drop dead’?
  • For any of our five propositions, would you have reached a different conclusion?
  • Could the inclusion of ‘dead’ be important for reasons that we have not considered?
  • Could there be downsides to dropping ‘dead’?
  • What are the key unanswered questions?

Please let us know what you think by visiting ResearchGate and adding a comment to our paper’s webpage.

This project was funded by the EuroQol Research Foundation. The views expressed are those of the authors and do not represent the views of the EuroQol Group.

Citation

Sampson, C., Parkin, D. and Devlin, N., 2020. Drop Dead: Is Anchoring at ‘Dead’ a Theoretical Requirement in Health State Valuation? OHE Research Paper, London: Office of Health Economics. Available at: https://www.ohe.org/publications/drop-dead-anchoring-%E2%80%98dead%E2%80%99-theoretical-requirement-health-state-valuation

Related Research

Shah, K.K., Ramos-Goñi, J.M., Kreimeier, S. and Devlin, N.J., 2020. An exploration of methods for obtaining 0 = dead anchors for latent scale EQ-5D-Y values. The European Journal of Health Economics, 21(7), pp.1091–1103. 10/ghmxn9.

Devlin, N., Buckingham, K., Shah, K., Tsuchiya, A., Tilling, C., Wilkinson, G. and van Hout, B., 2013. A comparison of alternative variants of the lead and lag time TTO. Health Economics, 22(5), pp.517–532. 10/gd83zr.

  • EQ-5D and PROMs
  • Measuring and Valuing Outcomes
  • Research Papers

Related News

  • News
  • September 2020

Cornerstones of ‘Fair’ Drug Coverage

Read more
  • News
  • January 2020

Anchoring Latent Scale Values for the EQ-5D-Y at 0 = Dead

Read more
  • News
  • September 2019

HTA and Payment Mechanisms for New Drugs to Tackle AMR

Read more
  • News
  • July 2019

Assessing the Life-cycle Value of Second-generation Antipsychotics in Sweden and the UK

Read more
footer_ohe_logo

Leading intellectual authority on global health economics

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Education

Events

About Us

OHE Experts

Contact Us

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Privacy Policy

Cookies Policy

© 2023 Website Design

An error has occurred, please try again later.An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in settings.

 Twitter
 Facebook
 LinkedIn
 Copy
 Email
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!